Exploring Supervised and Real-World Mobility in People with Parkinson’s Disease with and without Nocturnal Hypokinesia
Objective: To evaluate supervised and real-world mobility in people with Parkinson’s disease (PwPD) with and without nocturnal hypokinesia (NH). Background: Mobility impairment and NH are…Beyond constipation: gastrointestinal phenomena in Parkinson’s disease
Objective: To describe the prevalence of gastrointestinal manifestations in patients with Parkinson's disease in a Brazilian movement disorders outpatient clinic and evaluate their associated factors…Misinterpretation of Hypnagogic/hypnopompic Experiences as Hallucinations in Parkinson’s Disease
Objective: To investigate whether hypnagogic/hypnopompic experiences are clinically misinterpreted as hallucinations in Parkinson’s disease. Background: In Lewy body disorders, the progression of the disease can…Comorbidity of schizophrenia and Parkinson’s disease: a clinical case report
Objective: To describe the case of a patient with paranoid schizophrenia followed by the onset of the Parkinson’s disease at the 44-year age Background: Currently…Diagnostic Challenges in Functional Neurological Disorder: Convergent Psychogenic Non-Epileptic Seizures and Psychosis
Objective: To dissect the diagnostic challenges in distinguishing Functional Neurological Disorder (FND) coexisting with psychosis, highlighting the imperative for comprehensive and nuanced neuro-psychiatric assessment. Background:…Ibudilast, a Phosphodiesterase Inhibitor, Alleviates Huntington’s Disease Pathology through Neuroinflammation Modulation and Signaling Pathway Regulation in a Rat Model
Objective: This research aims to assess whether Ibudilast (IBD), a phosphodiesterase IV (PDE IV) inhibitor, can mitigate the damage induced by 3-nitropropionic acid (3-NP) in…Rare Clinical Manifestation of Tardive Dyskinesia In Schizophrenic Patient on Quetiapine and Sertraline: A Case Report
Objective: To underscore the rarity of tardive dyskinesia manifestation in a schizophrenic patient, prescribed second-generation DRBA agents, quetiapine and SSRI sertraline. Background: Tardive dyskinesia is…PD in Tanzania: representative in city dwellers, absent in nomadic tribespeople?
Objective: To investigate the aetiology of PD demographically in an under researched region. Background: PD monogenic and susceptibility risk factors explain little to none of…Abstract: Trends in Movement Disorders related death in the United States from 1999 to 2020
Objective: We aimed to analyze the mortality and prevalence of movement disorders in the United States from 1999 to 2020 to compare disparities among various…Monitoring Progress: Use of the Behavioral Dyscontrol Scale-2 (BDS-2) in FXTAS (Fragile X-associated Tremor Ataxia Syndrome) Progression
Objective: To investigate the use of the neuropsychological BDS-2 measures and its correlation with MRI findings and FXTAS stages[1] Background: Fragile X-associated Tremor Ataxia Syndrome…
- « Previous Page
- 1
- …
- 170
- 171
- 172
- 173
- 174
- …
- 181
- Next Page »